Palliative chemotherapy for breast cancer: A population-based cohort study of emergency hospital admissions and place of death.
breast cancer
emergency hospital admissions
end of life morbidity
palliative chemotherapy
place of death
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
01
12
2021
received:
10
11
2020
accepted:
28
03
2022
pubmed:
28
5
2022
medline:
14
7
2022
entrez:
27
5
2022
Statut:
ppublish
Résumé
Patients with incurable breast cancer may be treated with chemotherapy to improve cancer-related symptoms, quality of life and survival. We examined the association between use of palliative chemotherapy towards the end of life in breast cancer patients and outcomes including unplanned hospital admission and place of death. A total of 10,966 women, treated with palliative chemotherapy for breast cancer (diagnosed 1995-2017 in England) within the 2 years prior to death (death between 2014 and 2017), were analysed. Logistic regression (outcome = emergency hospital admission in last 90 days of life yes/no; outcome = place of death hospital/other) was performed, adjusting for line of palliative chemotherapy in the last 90 days of life and patient demographics. The odds of hospital admission reduced with increasing line of chemotherapy received (1st line odds ratio [OR] = 2.7, 2nd line OR = 2.1, 3rd line OR = 1.9, 4th+ line OR = 1.7; baseline chemotherapy) in last 90 days of life. A similar relationship was observed for hospital death (1st line OR = 2.4, 2nd line OR = 2.1, 3rd line OR = 1.7, 4th+ line OR = 1.5). This study finds palliative chemotherapy towards the end of life to be associated with increased odds of unplanned hospital admissions and hospital death. These findings can be used to inform discussions between patients and healthcare professionals towards the end of life.
Types de publication
Journal Article
Langues
eng
Pagination
e13598Subventions
Organisme : Cancer Research UK
ID : C8225/A21133
Pays : United Kingdom
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Audrey, S., Abel, J., Blazeby, J. M., Falk, S., & Campbell, R. (2008). What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study. BMJ (Clinical Research Ed.), 337(jul31 3), a752. https://doi.org/10.1136/bmj.a752
Blum, J. L., Barrios, C. H., Feldman, N., Verma, S., McKenna, E. F., Lee, L. F., Scotto, N., & Gralow, J. (2012). Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 136(3), 777-788. https://doi.org/10.1007/s10549-012-2288-x
Bright, C. J., Lawton, S., Benson, S., Bomb, M., Dodwell, D., Henson, K. E., McPhail, S., Miller, L., Rashbass, J., Turnball, A., & Smittenaar, R. (2019). Corrigendum to: Data resource profile: The systemic anti-Cancer therapy (SACT) dataset. International Journal of Epidemiology, 49(1), 354-354. https://doi.org/10.1093/ije/dyz249
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., Andre, F., Harbeck, N., Augilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortes, J., Curigliano, G., Dieras, V., El Saghir, N. S., Eniu, A., & Winer, E. (2018). 4th ESO-ESMO international consensus guidelines for advanced breast Cancer (ABC 4). Annals of Oncology, 29(8), 1634-1657. https://doi.org/10.1093/annonc/mdy192
Coupland, V. H., Madden, P., Jack, R. H., Moller, H., & Davies, E. A. (2011). Does place of death from cancer vary between ethnic groups in south East England? Palliative Medicine, 25(4), 314-322. https://doi.org/10.1177/0269216310395986
Du, X. L., Osborne, C., & Goodwin, J. S. (2002). Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. Journal of Clinical Oncology, 20(24), 4636-4642. https://doi.org/10.1200/JCO.2002.05.088
Epstein, A. S., Prigerson, H. G., OReilly, E. M., & Maciejewski, P. K. (2016). Discussions of life expectancy and changes in illness understanding in patients with advanced Cancer. Journal of Clinical Oncology, 34(20), 2398-2403. https://doi.org/10.1200/JCO.2015.63.6696
Fallowfield, L. J., Jenkins, V. A., & Beveridge, H. A. (2002). Truth may hurt but deceit hurts more: Communication in palliative care. Palliative Medicine, 16(4), 297-303. https://doi.org/10.1191/0269216302pm575oa
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007). Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology, 608, 1-22. https://doi.org/10.1007/978-0-387-74039-3_1
Government, D. o. C. a. L. (2015). All ranks, deciles and scores for the indices of deprivation, and population denominators.
Grunfeld, E. A., Maher, E. J., Browne, S., Ward, P., Young, T., Vivat, B., Walker, G., Wilson, C., Potts, H., Westcombe, A., Richards, M., & Ramirez, A. (2006). Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. Journal of Clinical Oncology, 24(7), 1090-1098. https://doi.org/10.1200/JCO.2005.01.9208
Henson, K. E., Elliss-Brookes, L., Coupland, V. H., Payne, E., Vernon, S., Rous, B., & Rashbass, J. (2019). Data resource profile: National Cancer Registration Dataset in England. International Journal of Epidemiology, 49, 16-16h. https://doi.org/10.1093/ije/dyz076
Jung, D., Hwang, S., You, H. J., & Lee, J. (2012). The realities and associated factors of palliative chemotherapy near the end of life in the patients enrolled in palliative care unit. Korean Journal of Family Medicine, 33(1), 44-50. https://doi.org/10.4082/kjfm.2012.33.1.44
Keating, N. L., Landrum, M. B., Rogers, S. O. Jr., Baum, S. K., Virnig, B. A., Huskamp, H. A., Earle, C. C., & Kahn, K. L. (2010). Physician factors associated with discussions about end-of-life care. Cancer, 116(4), 998-1006. https://doi.org/10.1002/cncr.24761
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015). A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials, 16(495), 1-14. https://doi.org/10.1186/s13063-015-1023-4
Koffman, J., Ho, Y. K., Davies, J., Gao, W., & Higginson, I. J. (2014). Does ethnicity affect where people with cancer die? A population-based 10 year study. PLoS ONE, 9(4), e95052. https://doi.org/10.1371/journal.pone.0095052
Näppä, U., Lindqvist, O., Rasmussen, B. H., & Axelsson, B. (2011). Palliative chemotherapy during the last month of life. Annals of Oncology, 22(11), 2375-2380. https://doi.org/10.1093/annonc/mdq778
National Cancer Registration and Analysis Service. (2019). 30-Day Mortality after Receiving SACT in England, 2015-2016 Workbook. NCRAS. Retrieved from http://www.chemodataset.nhs.uk/reports/
National Cancer Registration and Analysis Service. (2020). 30 Day Mortality Post-SACT CMAR Workbook-November 2020. NCRAS.
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology, 5(6), 649-655. https://doi.org/10.1097/00000421-198212000-00014
Park, I. H., Lee, K. S., & Ro, J. (2015). Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clinical Breast Cancer, 15(1), e55-e62. https://doi.org/10.1016/j.clbc.2014.09.001
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M., Carrington Reid, M., Berlin, D., Adelson, K., Neugut, A., & Maciejewski, P. K. (2015). Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncology, 1(6), 778-784. https://doi.org/10.1001/jamaoncol.2015.2378
Wallington, M., Saxon, E. B., Bomb, M., Smittenaar, R., Wickenden, M., McPhail, S., Rashbass, J., Chao, D., Dewar, J., Talbot, D., Peak, M., Perren, T., Wilson, C., & Dodwell, D. (2016). 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: A population-based, observational study. The Lancet Oncology, 17(9), 1203-1216. https://doi.org/10.1016/S1470-2045(16)30383-7
Wentlandt, K., Krzyzanowska, M. K., Swami, N., Rodin, G. M., Le, L. W., & Zimmermann, C. (2012). Referral practices of oncologists to specialized palliative care. Journal of Clinical Oncology, 30(35), 4380-4386. https://doi.org/10.1200/JCO.2012.44.0248
Wright, A. A., Zhang, B., Keating, N. L., Weeks, J. C., & Prigerson, H. G. (2014). Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: Prospective cohort study. BMJ (Clinical Research Ed.), 348(4), g1219-g1219. https://doi.org/10.1136/bmj.g1219